Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study
出版年份 2022 全文链接
标题
Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study
作者
关键词
-
出版物
Neurology and Therapy
Volume 11, Issue 2, Pages 815-834
出版商
Springer Science and Business Media LLC
发表日期
2022-04-12
DOI
10.1007/s40120-022-00345-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
- (2021) James F Howard et al. LANCET NEUROLOGY
- ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab
- (2020) John Vissing et al. JOURNAL OF NEUROLOGY
- Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations
- (2020) Hans-Hartmut Peter et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Update in immunosuppressive therapy of myasthenia gravis
- (2020) Agustina M. Lascano et al. AUTOIMMUNITY REVIEWS
- Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
- (2020) Konstantinos Lazaridis et al. Frontiers in Neurology
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis
- (2019) James F. Howard et al. NEUROLOGY
- Removal Characteristics of Immunoadsorption with the Tryptophan‐Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis
- (2019) Atsushi Ohkubo et al. THERAPEUTIC APHERESIS AND DIALYSIS
- Myasthenia gravis
- (2019) Nils Erik Gilhus et al. Nature Reviews Disease Primers
- Next-generation Fc receptor–targeting biologics for autoimmune diseases
- (2019) Adrian W. Zuercher et al. AUTOIMMUNITY REVIEWS
- Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses
- (2019) L. J. Blumberg et al. Science Advances
- M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study
- (2018) Leona E. Ling et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
- (2017) Peter Kiessling et al. Science Translational Medicine
- Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis
- (2016) Jeffrey T. Guptill et al. AUTOIMMUNITY
- International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r
- (2016) Ted M. Burns et al. MUSCLE & NERVE
- The MG Composite: A valid and reliable outcome measure for myasthenia gravis
- (2010) T. M. Burns et al. NEUROLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now